Viking Therapeutics plans to advance its obesity drug VK2735 to Phase III trials by late 2024, following Phase II results ...

Biostar Pharmaceuticals plans to raise funds through an IPO on the Hong Kong Stock Exchange, offering 14.6 million shares at ...

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. The UK ...

Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with ...

Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

Intellia Therapeutics reported positive Phase II results for its CRISPR therapy NTLA-2002, showing an 81% reduction in ...

Orion has discontinued its pain management candidate ODM-111 due to a narrow therapeutic window found in toxicology studies.

Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines ...

US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in ...